Integrated Approaches for Identifying Molecular Targets in Alcoholic

Status Completed

Clinical Trial Summary

Purpose: To improve the diagnosis and assessment of severity of acute alcoholic hepatitis Participants: Patients admitted to one of ten centers with acute alcoholic hepatitis Procedures (methods): Consecutive patients admitted with acute alcoholic hepatitis will be enrolled in an NIH U01 study of acute alcoholic hepatitis where liver tissue, blood and stool will be collected to discover and validate factors associated with diagnosis, severity of disease and survival.

Clinical Trial Description

The development of new targeted therapies for alcoholic hepatitis (AH) is one of the more urgent needs in clinical hepatology. To reach this goal, large multidisciplinary networks are required. The proposed initiative "Integrated Approaches for Identifying Molecular Targets in Alcoholic Hepatitis" (InTeam) will coordinate a multidisciplinary group composed of clinicians, physician-scientists, basic scientists and bioinformatics experts. The overarching hypothesis of InTeam is that the most rational way to provide a useful framework for future clinical trials in (AH) consists of the (i) determination of key drivers of the disease process, (ii) classification of molecular profiles and subtypes of AH, and (iii) identification of "druggable" targets based on both key drivers and molecular classification. Moreover, mouse models for AH are lacking making it impossible to evaluate promising targets in preclinical mouse studies in a meaningful manner. For this purpose, InTeam will integrate data obtained from molecular pathology studies in human AH and functional studies of key pathways in animal models. The proposed InTeam consortium includes three research projects, ten clinical centers, a Human Biorepository and a Mouse Models Core. The Human Biorepository Core will generate the to-date largest collection of samples from patients with AH from 10 academic liver centers and a comprehensive database that will serve as a basis for the proposed translational studies and be a valuable asset for the broader scientific community. The Mouse Models core will conduct murine studies after establishing and evaluating mouse models of AH based on the pathophysiology and molecular drivers of human AH determined by this consortium. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02075918
Study type	Observational
Source	University of Pittsburgh
Contact
Status	Completed
Phase
Start date	May 2014
Completion date	May 31, 2019

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04066179` - Efficacy of Monotherapy vs Combination Therapy of Corticosteroids With GCSF in Severe Alcoholic Hepatitis Patients.	N/A
Completed	`NCT03732586` - Effect of Omega 5 Fatty Acid as an Adyuvant Treatment to Prednisone in Patients With Severe Alcoholic Hepatitis	N/A
Completed	`NCT01476995` - Prognostic Indicators as Provided by the EPIC ClearView	N/A
Completed	`NCT00962442` - N-Acetylcysteine in Severe Acute Alcoholic Hepatitis	Phase 3
Not yet recruiting	`NCT06307522` - MRG-001 in Patients With Alcoholic Hepatitis	Phase 2
Recruiting	`NCT05018481` - HA35 Moderate Alcoholic Hepatitis (AH) Study	Early Phase 1
Completed	`NCT04544020` - Changes in gUt micRobiota After Enteral Feeding (in Alcoholic Hepatitis)
Recruiting	`NCT04088370` - Peripheral Blood Mononuclear Cells Response In Healthy Controls, Heavy Drinkers, and Patients With Alcoholic Hepatitis
Completed	`NCT04235855` - EUS Guided Liver Biopsy - Will it Give Better Yield, More Tissue With Less Complication?	N/A
Active, not recruiting	`NCT02344680` - Liver Fibrosis in Zambian HIV-HBV Co-infected Patients
Completed	`NCT00851981` - Randomized, Controlled Trial of S-adenosylmethionine in Alcoholic Liver Disease	Phase 2
Completed	`NCT04084522` - Effect of Saturated Fat (Desi Ghee) on Gut-Liver Axis in Alcoholic Hepatitis	N/A
Completed	`NCT05840640` - Granulocyte Colony Stimulating Factor Four Week Plus N-Acetyl Cysteine in Severe Alcoholic Hepatitis	Phase 4
Recruiting	`NCT03069300` - N-ACetylcysteine to Reduce Infection and Mortality for Alcoholic Hepatitis	Phase 3
Terminated	`NCT02039219` - Trial of Obeticholic Acid in Patients With Moderately Severe Alcoholic Hepatitis (AH)	Phase 2
Completed	`NCT02019056` - Efficacy and Safety of MG in the Patients With Alcoholic Fatty Liver Disease and Alcoholic Hepatitis	Phase 2
Completed	`NCT01245257` - Effects of Prednisolone and Pentoxifylline on the Regulation of Urea Synthesis in Alcoholic Hepatitis	N/A
Completed	`NCT00388323` - Adipose Tissue Involvement in Alcohol-induced Liver Inflammation in Human	N/A
Recruiting	`NCT03845205` - Alcohol Treatment Outcomes Following Early vs. Standard Liver Transplant for SAH	N/A
Recruiting	`NCT03703674` - GCSF in Alcoholic Hepatitis	Phase 4

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Integrated Approaches for Identifying Molecular Targets in Alcoholic Hepatitis — InTeam

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms